[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"bloodpressure\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:bloodpressure":28},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,1,0,[8],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":13,"acronym":14,"eligibilityCriteria":15,"healthyVolunteers":16,"sex":17,"minAge":18,"maxAge":19,"enrollmentInfo":20,"targetDuration":4,"studyType":23,"phases":24,"briefSummary":26,"conditions":27,"keywords":29,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":35,"lastUpdatePostDateStruct":36,"startDateStruct":39,"completionDateStruct":41,"leadSponsor":43,"locationsCount":46},"100587906","effects-of-endogenous-gip-on-postprandial-blood-pressure-in-healthy-individuals-100587906",false,"NCT06934473","Effects of Endogenous GIP on Postprandial Blood Pressure in Healthy Individuals","GA-25","Inclusion Criteria:\n\n1. Age 18-40 years\n2. BMI between 18.5 and 29.9 kg\u002Fm2 (both included)\n3. Informed consent\n\nExclusion Criteria:\n\n1. Allergy or intolerance to ingredients included in the mixed meal\n2. History of Orthostatic Hypotension (OH) or Postural Orthostatic Tachycardia Syndrome (POTS) or other autonomic dysfunction at the discretion of the investigators\n3. Anaemia (haemoglobin below normal range \\\u003C7.3 mmol\u002FL for women and \\\u003C8.3 mmol\u002FL for men)\n4. Kidney disease (estimated glomerular filtration rate (eGFR) \\\u003C90 ml\u002Fmin\u002F1.73 m2) at screening\n5. Known liver disease and\u002For elevated plasma alanine aminotransferase (ALT) \\> three times the upper limit of normal at screening\n6. Treatment with antihypertensives\n7. Treatment with GLP-1RA (Glucagon-like Peptide-1 Receptor Agonist)\n8. Treatment with SNRI (Serotonin and Noradrenalin Reuptake Inhibitor) or treatment within two weeks before the first experimental day\n9. Any ongoing medication that the investigator evaluates would interfere with trial participation\n10. Any physical or psychological condition that the investigator evaluates would interfere with trial participation, including any acute or chronic illnesses\n11. Any concomitant disease or treatment that, at the discretion of the investigators, might jeopardize the participant's safety during the trial\n12. Alcohol\u002Fdrug abuse as per discretion of the investigators\n13. Pregnancy or breastfeeding\n14. Participation in any other clinical trial during the study period\n15. Mental incapacity or language barriers that preclude adequate understanding or cooperation or unwillingness to comply with trial requirements or pr discretion of the investigator",true,"ALL","18 Years","40 Years",{"count":21,"type":22},16,"ESTIMATED","INTERVENTIONAL",[25],"NA","The present study investigates the postprandial role of endogenous glucose-dependent insulinotropic polypeptide (GIP) on cardiovascular haemodynamics, hormone responses, and hypotensive symptoms during a tilt test.",[28],"Bloodpressure",[30,31,32,33],"Glucose-dependent insulinotropic polypeptide","GIP","GIP receptor antagonist","GIP(3-30)NH2","RECRUITING","2025-09-01",{"date":37,"type":38},"2025-09-08","ACTUAL",{"date":40,"type":38},"2025-05-21",{"date":42,"type":22},"2026-01-31",{"name":44,"class":45},"University Hospital, Gentofte, Copenhagen","OTHER",2]